KMG Fiduciary Partners LLC Reduces Position in Johnson & Johnson (NYSE:JNJ)

KMG Fiduciary Partners LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJFree Report) by 1.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 21,230 shares of the company’s stock after selling 248 shares during the quarter. KMG Fiduciary Partners LLC’s holdings in Johnson & Johnson were worth $3,328,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. RPG Investment Advisory LLC boosted its position in Johnson & Johnson by 1.2% in the second quarter. RPG Investment Advisory LLC now owns 4,876 shares of the company’s stock worth $807,000 after purchasing an additional 60 shares during the last quarter. FIDELIS iM LLC lifted its position in shares of Johnson & Johnson by 3.1% during the 4th quarter. FIDELIS iM LLC now owns 2,117 shares of the company’s stock valued at $374,000 after buying an additional 64 shares in the last quarter. TFG Advisers LLC lifted its position in shares of Johnson & Johnson by 0.4% during the 3rd quarter. TFG Advisers LLC now owns 18,330 shares of the company’s stock valued at $2,855,000 after buying an additional 67 shares in the last quarter. Kellett Wealth Advisors LLC lifted its position in shares of Johnson & Johnson by 3.8% during the 3rd quarter. Kellett Wealth Advisors LLC now owns 1,880 shares of the company’s stock valued at $293,000 after buying an additional 68 shares in the last quarter. Finally, Hutchinson Capital Management CA lifted its position in shares of Johnson & Johnson by 0.6% during the 3rd quarter. Hutchinson Capital Management CA now owns 10,566 shares of the company’s stock valued at $1,646,000 after buying an additional 68 shares in the last quarter. Hedge funds and other institutional investors own 68.40% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of a number of analyst reports. UBS Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $167.00 to $180.00 in a research report on Friday, December 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, March 13th. Morgan Stanley decreased their target price on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 24th. Wells Fargo & Company downgraded Johnson & Johnson from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $170.00 to $163.00 in a research note on Wednesday, December 13th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 28th. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $177.31.

Check Out Our Latest Analysis on JNJ

Johnson & Johnson Stock Performance

NYSE JNJ opened at $157.01 on Tuesday. The company has a market cap of $378.36 billion, a P/E ratio of 11.35, a P/E/G ratio of 2.66 and a beta of 0.53. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. The business’s 50 day moving average price is $159.48 and its 200-day moving average price is $156.87. Johnson & Johnson has a fifty-two week low of $144.95 and a fifty-two week high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The company had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. During the same quarter in the previous year, the business earned $2.35 EPS. Johnson & Johnson’s revenue was down 9.7% compared to the same quarter last year. Sell-side analysts predict that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th were issued a $1.19 dividend. This represents a $4.76 annualized dividend and a dividend yield of 3.03%. The ex-dividend date of this dividend was Friday, February 16th. Johnson & Johnson’s dividend payout ratio is 34.47%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.